| Title |
Advances with RNA interference in Alzheimer’s disease research
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2013
|
| DOI | 10.2147/dddt.s40229 |
| Pubmed ID | |
| Authors |
Shun Chen, Xuemei Ge, Yinghui Chen, Nan Lv, Zhenguo Liu, Weien Yuan |
| Abstract |
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 154 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 152 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 35 | 23% |
| Student > Master | 26 | 17% |
| Researcher | 20 | 13% |
| Student > Ph. D. Student | 20 | 13% |
| Other | 6 | 4% |
| Other | 16 | 10% |
| Unknown | 31 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 39 | 25% |
| Biochemistry, Genetics and Molecular Biology | 29 | 19% |
| Neuroscience | 15 | 10% |
| Medicine and Dentistry | 10 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Other | 15 | 10% |
| Unknown | 37 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2021.
All research outputs
#1,933,246
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#91
of 2,254 outputs
Outputs of similar age
#18,199
of 292,111 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 20 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,111 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.